Blackstone commits up to $1.3bn to Apogee’s skin drug
Blackstone Inc is committing as much as $1.3bn in structured financing to Apogee Therapeutics Inc, supporting the biotech’s efforts to advance a potential rival to the widely used eczema treatment Dupixent, according to a report by Bloomberg.
Original Source
Read the full article at Privateequitywire →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.